title: Use of temperature-controlled laminar airflow in the management of atopic asthma: clinical evidence and experience.
abstract: Avoidance of allergens in the treatment of asthma has hitherto not achieved significant benefit despite the strong evidence that allergy both increases severity and contributes to exacerbations of asthma. House dust mite, cat and dog allergens are the most common perennial allergic triggers and most avoidance strategies have focused on reducing exposures in bedrooms. Cochrane reviews have suggested that they neither significantly reduce allergen levels nor improve asthma. While the lack of efficacy may be assumed to be a consequence of exposures occurring outside the bedroom, prolonged sleep is associated with increased susceptibility to bronchospasm and airway inflammation. Thus, if efficient reductions in allergen exposure could be achieved during sleep, it might be expected that this would result in significant improvements in control of asthma. The temperature-controlled laminar airflow (TLA) is a system which can be employed over beds in a domestic environment and results in massive reductions in particulate exposure of recumbent subjects, including highly respirable allergens such as Fel. D1 from cats. Trials of TLA have demonstrated highly significant improvements in asthma quality of life and reductions on airway inflammation as monitored by exhaled nitric oxide levels. Furthermore, in patients with the worst disease, severe exacerbation frequency was significantly reduced. Based on UK health-service costs, the use of TLA falls well below the National Institute for Health and Care Excellence (NICE) threshold for the incremental cost effectiveness ratio (ICER) per quality adjusted life year (QALY). Indeed, for those with frequent exacerbations, it is cost saving and should be prescribed for such allergic asthmatic patients.
authors.affiliation: Department of Paediatrics, Imperial College London, London W2 1PG, UK.
authors.forename: John O
authors.initials: JO
authors.lastname: Warner
mesh_terms: D000485:Allergens / Q000276:immunology*; D000818:Animals; D001249:Asthma / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D003362:Cost-Benefit Analysis; D004780:Environment, Controlled; D006801:Humans; D007249:Inflammation / Q000276:immunology / Q000628:therapy; D009569:Nitric Oxide / Q000378:metabolism; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D012720:Severity of Illness Index; D013696:Temperature
chemical_list: D000485:Allergens; D009569:Nitric Oxide
keywords: allergen avoidance; allergic asthma; environmental control; particle exposure; temperature controlled laminar airflow